Search

Your search keyword '"Byron Vaughn"' showing total 10 results
Start Over Author "Byron Vaughn"
10 results on '"Byron Vaughn"'

1. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

Author

Rustem, Abdulkhakov, Norasiah, Abu Bakar, Humberto, Aguilar, Diego, Aizenberg, Hale, Akpinar, Evangelos, Akriviadis, Olga, Alexeeva, Bagdadi, Alikhanov, Andres, Alvarisqueta, Ashwin, Ananthakrishnan, Jane, Andrews, Tomasz, Arlukowicz, Nathan, Atkinson, Ozlen, Atug, Mauro, Bafutto, Jozef, Balaz, George, Bamias, Marko, Banic, Andrey, Baranovsky, Guerino, Barbalaco Neto, Metin, Basaranoglu, Curtis, Baum, Stefan, Baydanov, William, Bennetts, Fatih, Besisik, Sudhir, Bhaskar, Andrzej, Bielasik, Leonid, Bilianskyi, Bahri, Bilir, Pavol, Blaha, Verle, Bohman, Julia, Borissova, Vladimir, Borzan, Francisco, Bosques-Padilla, Yoram, Bouhnik, James, Brooker, Tetiana, Budko, Igor, Budzak, Ivan, Bunganic, Jonathon, Chapman, Azlida, Che' Aun, Tatiana, Chernykh, Michael, Chiorean, Ivan, Chopey, Dimitrios, Christodoulou, Pui Shan, Chu, Galina, Chumakova, Andrew, Cummins, Robert, Cunliffe, Mirjana, Cvetkovic, Ulku, Dagli, Wit Cezary, Danilkiewicz, Olena, Datsenko, Carlos Fernando, de Magalhães Francesconi, Henry, Debinski, Elena, Deminova, Jelena, Derova, John Nik, Ding, Julia, Dmitrieva, Oleg, Dolgikh, Tomas, Douda, Piotr, Drobinski, Gerald, Dryden, Pedro, Duarte Gaburri, George Aaron, DuVall, Mikhail, Dvorkin, Craig, Ennis, Yusuf, Erzin, Galyna, Fadieienko, Oleksandr, Fediv, Olga, Fedorishina, Miroslav, Fedurco, Roland, Fejes, Jorge, Fernandez, Monica Lorena, Fernandez, Lucky, Flores, Bradley, Freilich, Keith, Friedenberg, Sergio, Fuster, Beata, Gawdis-Wojnarska, Fabio Leonel, Gil Parada, Edgardo Daniel, Gimenez, Nataliia, Golovchenko, Oleksandr, Golovchenko, Maciej, Gonciarz, Can, Gonen, Glenn, Gordon, Milos, Gregus, Vladimir, Grinevich, Rogelio, Guajardo Rodriguez, Stephen, Hall, John, Hanson, Marek, Hartleb, Xavier, Hebuterne, Peter, Hendy, Robert, Herring, David, Hetzel, Peter, Higgins, Raouf, Hilal, Ida Normiha, Hilmi, Tibor, Hlavaty, Richard, Holman, Gerald, Holtmann, John, Hong, Frantisek, Horvath, Ihor, Hospodarskyy, Irena, Hrstic, Sadettin, Hulagu, Luis Alberto, Ibarra Verdugo, Ikechukwu, Ibegbu, Stephen, Inns, Vladimir, Ivashkin, James, Izanec, Rajesh, Jain, Zofia, Jamrozik-Kruk, Victor, Kamburov, John, Karagiannis, Tarkan, Karakan, Marek, Karczewski, Irina, Kasherininova, Seymour, Katz, Barry, Kaufman, Edita, Kazenaite, Irina, Kholina, Sunil, Khurana, Jaroslaw, Kierkus, Anzela, Kiselevska, Dariusz, Kleczkowski, Volodymyr, Klymenko, Slavko, Knezevic, Malgorzata, Kondusz-Szklarz, Natalya, Korablina, Bartosz, Korczowski, Lyubomir, Kosturkov, Iskren, Kotzev, Georgios, Kouklakis, Ioannis, Koutroubakis, Richard, Krause, Ian, Kronborg, Miodrag, Krstic, Zeljko, Krznaric, Mikolaj, Krzyzanowski, Grazyna, Kulig, Karin, Kull, Limas, Kupcinskas, Mark, Lamet, Tatjana, Latinovic Radakovic, Rupert, Leong, Wai Keung, Leung, Henry, Levine, Michael Kin Kong, Li, Lúcia, Libanez Bessa Campelo Braga, Maria, Livzan, Tetiana, Lohdanidi, Maria Helena, Louzada Pereira, John, Lowe, Kresimir, Luetic, Milan, Lukas, Yurii, Lymar, Finlay, Macrae, Anu, Mäelt, Igor, Maev, Arkadiusz, Mamos, Gerasimos, Mantzaris, Benno, Margus, Ivanka, Marinova, Inna, Markevych, Mario, Markov, Srdjan, Markovic, Juan Ricardo, Marquez Velasquez, Felipe, Mazzoleni, Konstantinos, Mimidis, Brent, Mitchell, Gregory, Moore, Luis Alonso, Morales Garza, Salvatore, Moscatello, Yuriy, Mostovoy, Reme, Mountifield, Aleksandar, Nagorni, Viacheslav, Neshta, Andrey, Obrezan, Oleksandr, Oliinyk, Genoile, Oliveira Santana Silva, Maria, Orzeszko, Vladimir, Pavlenko, Dimitar, Pavlov, Mariana, Penkova, Sasa, Peric, Plamen, Petkov, Asen, Petrov, Plamen, Petrov, Michaela, Petrova, Raymond, Phillips, Sergio, Pintor Chacon, Igor, Polianskyi, Ludmyla, Prystupa, Mykhailo, Pugach, Ana Teresa, Pugas Carvalho, Aldis, Pukitis, Jiri, Pumprla, Volodymyr, Pyrogovskyy, Istvan, Racz, Graham, Radford-Smith, Raja Affendi, Raja Ali, Daniel, Ramos Castañeda, Odery, Ramos Júnior, David, Rausher, Andrey, Rebrov, Jaroslaw, Regula, Amir, Rezk, Viktoriia, Reznikova, Iaroslava, Rishko, Xavier, Roblin, Grigory, Rodoman, Carlos Arturo, Rojas Rodriguez, Jerzy, Rozciecha, David, Rubin, Maciej, Rupinski, Jacek, Rzucidlo, Oleg, Sablin, Halil, Sahin, Rosemi, Salleh, Douglas, Samuel, Antonio, Scafuto Scotton, Robert, Schnabel, Michael, Schulman, Michael, Schultz, John, Scott, Shahriar, Sedghi, Ahmad, Shaban, Marina, Shapina, Natalia, Shaposhnikova, Oksana, Shchukina, Alex, Sherman, Irina, Shumikhina, Vladimir, Simanenkov, Vladislav, Simonov, Giedrius, Simulionis, Igor, Skrypnyk, Zbigniew, Sliwowski, Jan, Smid, Mahmood, Solaiman, Najm, Soofi, Konstantinos, Soufleris, Zoia, Spassova, Mykola, Stanislavchuk, Krystyna, Stec-Michalska, Jonathas, Stifft, Simeon, Stoinov, Girgina, Stoyanova, Keith, Sultan, Lindsey, Surace, Dimitar, Takov, Jaak, Tälli, Ludmila, Tankova, Hugo, Tanno, Dino, Tarabar, Elias, Tarakji, Konstantin, Tchernev, Hoi Poh, Tee, Lena, Thin, Carlton, Thomas, Irina, Tishaeva, Tsveta, Todorova, Oleksandr, Tokarenko, Ivars, Tolmanis, Ratko, Tomasevic, Vasiliy, Trofimov, Zsolt, Tulassay, Belkis, Unsal, Alma, Uzunova-Genova, John, Valentine, Ekaterina, Valuyskikh, Eduardo, Vasconcellos, Galina, Vasileva, Sergiy, Vasylyuk, Byron, Vaughn, Francisco, Velazquez, Vadym, Vizir, Borislav, Vladimirov, Miroslava, Volfova, Petr, Vyhnalek, Ian, Wallace, Marek, Waluga, William, Watkins, John, Weber, Anna, Wiechowska-Kozlowska, Nathaniel, Winstead, Pawel, Wojtkiewicz, Barbara, Wozniak-Stolarska, Bruce, Yacyshyn, Alexey, Yakovlev, Ziad, Younes, Lígia, Yukie Sassaki, Ilhami, Yuksel, Jan, Zachar, Cyrla, Zaltman, Natasa, Zdravkovic Petrovic, Vyacheslav, Zhdan, Maryna, Zinchenko, Maciej, Zymla, Rubin, David T, Dotan, Iris, DuVall, Aaron, Bouhnik, Yoram, Radford-Smith, Graham, Higgins, Peter D R, Mishkin, Daniel S, Arrisi, Pablo, Scalori, Astrid, Oh, Young S, Tole, Swati, Chai, Akiko, Chamberlain-James, Kirsten, Lacey, Stuart, McBride, Jacqueline, and Panés, Julian

Published
2022
Full Text
View/download PDF

6. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Author

Laurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, Millie Long, Matthieu Allez, Pascal Juillerat, Alessandro Armuzzi, Edward V Loftus, Elham Ostad-Saffari, Astrid Scalori, Young S Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Stuart Lacey, William J Sandborn, Humberto Aguilar, Tariq Ahmad, Evangelos Akriviadis, Xavier Aldeguer Mante, Istvan Altorjay, Ashwin Ananthakrishnan, Vibeke Andersen, Montserrat Andreu Garcia, Guy Aumais, Irit Avni-Biron, Jeffrey Axler, Kamran Ayub, Filip Baert, Mauro Bafutto, George Bamias, Isaac Bassan, Curtis Baum, Laurent Beaugerie, Brian Behm, Pradeep Bekal, Michael Bennett, Fernando Bermejo San Jose, Charles Bernstein, Dominik Bettenworth, Sudhir Bhaskar, Livia Biancone, Bahri Bilir, Michael Blaeker, Stuart Bloom, Verle Bohman, Francisco Javier Bosques Padilla, Yoram Bouhnik, Gerd Bouma, Raymond Bourdages, Stephan Brand, Brian Bressler, Markus Brückner, Carsten Buening, Franck Carbonnel, Thomas Caves, Jonathon Chapman, Jae Hee Cheon, Naoki Chiba, Camelia Chioncel, Dimitrios Christodoulou, Martin Clodi, Albert Cohen, Gino Roberto Corazza, Richard Corlin, Rocco Cosintino, Fraser Cummings, Robin Dalal, Silvio Danese, Marc De Maeyer, Carlos Fernando De Magalhães Francesconi, Aminda De Silva, Henry Debinski, Pierre Desreumaux, Olivier Dewit, Geert D'Haens, Sandra Di Felice Boratto, John Nik Ding, Tyler Dixon, Gerald Dryden, George Aaron Du Vall, Matthias Ebert, Ana Echarri Piudo, Robert Ehehalt, Magdy Elkhashab, Craig Ennis, Jason Etzel, Jan Fallingborg, Brian Feagan, Roland Fejes, Daniel Ferraz de Campos Mazo, Valéria Ferreira de Almeida Borges, Andreas Fischer, Alan Fixelle, Mark Fleisher, Sharyle Fowler, Bradley Freilich, Keith Friedenberg, Walter Fries, Csaba Fulop, Mathurin Fumery, Sergio Fuster, Gyula G Kiss, Santiago Garcia Lopez, Sonja Gassner, Kanwar Gill, Cyrielle Gilletta de Saint Joseph, Philip Ginsburg, Paolo Gionchetti, Eran Goldin, Adrian-Eugen Goldis, Hector Alejandro Gomez Jaramillo, Maciej Gonciarz, Glenn Gordon, Daniel Green, Jean-Charles Grimaud, Rogelio Guajardo Rodriguez, Zoltan Gurzo, Alexandra Gutierrez, Tibor Gyökeres, Ki Baik Hahm, Stephen Hanauer, John Hanson, William Harlan III, Peter Hasselblatt, Buhussain Hayee, Xavier Hebuterne, Peter Hendy, Melvin Heyman, Peter Higgins, Raouf Hilal, Pieter Hindryckx, Frank Hoentjen, Peter Hoffmann, Frank Holtkamp-Endemann, Gerald Holtmann, Gyula Horvat, Stefanie Howaldt, Samuel Huber, Ikechukwu Ibegbu, Maria Isabel Iborra Colomino, Peter Irving, Kim Isaacs, Kiran Jagarlamudi, Rajesh Jain, Sender Jankiel Miszputen, Jeroen Jansen, Jennifer Jones, John Karagiannis, Nicholas Karyotakis, Arthur Kaser, Lior Katz, Seymour Katz, Leo Katz, Nirmal Kaur, Edita Kazenaite, Reena Khanna, Sunil Khurana, Joo Sung Kim, Young-Ho Kim, Sung Kook Kim, Dongwoo Kim, Jochen Klaus, Dariusz Kleczkowski, Pavel Kohout, Bartosz Korczowski, Georgios Kouklakis, Ioannis Koutroubakis, Richard Krause, Tunde Kristof, Ian Kronborg, Annette Krummenerl, Limas Kupcinskas, Jorge Laborda Molteni, David Laharie, Adi Lahat-zok, Jonghun Lee, Kang-Moon Lee, Rupert Leong, Henry Levine, Jimmy Limdi, James Lindsay, Nilesh Lodhia, Edward Loftus, Randy Longman, Pilar Lopez Serrano, Edouard Louis, Maria Helena Louzada Pereira, John Lowe, Stefan Lueth, Milan Lukas, Giovanni Maconi, Finlay Macrae, Laszlo Madi-Szabo, Uma Mahadevan-Velayos, Everson Fernando Malluta, Fazia Mana, Peter Mannon, Gerasimos Mantzaris, Ignacio Marin Jimenez, Maria Dolores Martin Arranz, Radu-Bogdan Mateescu, Felipe Mazzoleni, Agnieszka Meder, Ehud Melzer, Jessica Mertens, Konstantinos Mimidis, Brent Mitchell, Tamas Molnar, Gregory Moore, Luis Alonso Morales Garza, Reme Mountifield, Vinciane Muls, Charles Murray, Bela Nagy, Markus Neurath, Augustin Nguyen, Remo Panaccione, William Pandak, Julian Panes Diaz, Jihye Park, Luca Pastorelli, Bhaktasharan Patel, Markus Peck-Radosavljevic, Gyula Pecsi, Farhad Peerani, Javier Perez Gisbert, Martin Pesta, Robert Petryka, Raymond Phillips, Marieke Pierik, Vijayalakshmi Pratha, Vlastimil Prochazka, Istvan Racz, Graham Radford-Smith, Daniel Ramos Castañeda, Odery Ramos Júnior, Jaroslaw Regula, Jean-Marie Reimund, Bryan Robbins, Xavier Roblin, Francesca Rogai, Gerhard Rogler, Jerzy Rozciecha, David Rubin, Azalia Yuriria Ruiz Flores, Maciej Rupinski, Grazyna Rydzewska, Sumona Saha, Simone Saibeni, Agnes Salamon, Zoltan Sallo, Bruce Salzberg, Douglas Samuel, Sunil Samuel, William Sandborn, Edoardo Vincenzo Savarino, Anja Schirbel, Robert Schnabel, Stefan Schreiber, John Scott, Shahriar Sedghi, Frank Seibold, Jakob Seidelin, Ursula Seidler, Ahmad Shaban, Ira Shafran, Aasim Sheikh, Alex Sherman, Haim Shirin, Patryk Smolinski, Geun Am Song, Konstantinos Soufleris, Alexander Speight, Dirk Staessen, Andreas Stallmach, Michael Staun, Daniel Stein, Hillary Steinhart, Jonathas Stifft, David Stokesberry, Andreas Sturm, Keith Sultan, Gyorgy Szekely, Kuldeep Tagore, Hugo Tanno, Lena Thin, Syed Thiwan, Carlton Thomas, Michal Tichy, Gabor Tamas Toth, Zsolt Tulassay, Jan Ulbrych, John Valentine, Marta Varga, Eduardo Vasconcellos, Byron Vaughn, Brenda Velasco, Francisco Velazquez, Severine Vermeire, Erica Villa, Aron Vincze, Harald Vogelsang, Miroslava Volfova, Lucine Vuitton, Petr Vyhnalek, Peter Wahab, Jens Walldorf, Mattitiahu Waterman, John Weber, L. Michael Weiss, Anna Wiechowska-Kozlowska, Elise Wiesner, Thomas Witthoeft, Robert Wohlman, Barbara Wozniak-Stolarska, Bruce Yacyshyn, Byong-Duk Ye, Ziad Younes, Lígia Yukie Sassaki, Cyrla Zaltman, Stefan Zeuzem, Neurosurgery, ANS - Neurovascular Disorders, Gastroenterology and Hepatology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Peyrin-Biroulet L., Hart A., Bossuyt P., Long M., Allez M., Juillerat P., Armuzzi A., Loftus E.V., Ostad-Saffari E., Scalori A., Oh Y.S., Tole S., Chai A., Pulley J., Lacey S., Sandborn W.J., Aguilar H., Ahmad T., Akriviadis E., Aldeguer Mante X., Altorjay I., Ananthakrishnan A., Andersen V., Andreu Garcia M., Aumais G., Avni-Biron I., Axler J., Ayub K., Baert F., Bafutto M., Bamias G., Bassan I., Baum C., Beaugerie L., Behm B., Bekal P., Bennett M., Bermejo San Jose F., Bernstein C., Bettenworth D., Bhaskar S., Biancone L., Bilir B., Blaeker M., Bloom S., Bohman V., Bosques Padilla F.J., Bouhnik Y., Bouma G., Bourdages R., Brand S., Bressler B., Bruckner M., Buening C., Carbonnel F., Caves T., Chapman J., Cheon J.H., Chiba N., Chioncel C., Christodoulou D., Clodi M., Cohen A., Corazza G.R., Corlin R., Cosintino R., Cummings F., Dalal R., Danese S., De Maeyer M., De Magalhaes Francesconi C.F., De Silva A., Debinski H., Desreumaux P., Dewit O., D'Haens G., Di Felice Boratto S., Ding J.N., Dixon T., Dryden G., Du Vall G.A., Ebert M., Echarri Piudo A., Ehehalt R., Elkhashab M., Ennis C., Etzel J., Fallingborg J., Feagan B., Fejes R., Ferraz de Campos Mazo D., Ferreira de Almeida Borges V., Fischer A., Fixelle A., Fleisher M., Fowler S., Freilich B., Friedenberg K., Fries W., Fulop C., Fumery M., Fuster S., G Kiss G., Garcia Lopez S., Gassner S., Gill K., Gilletta de Saint Joseph C., Ginsburg P., Gionchetti P., Goldin E., Goldis A.-E., Gomez Jaramillo H.A., Gonciarz M., Gordon G., Green D., Grimaud J.-C., Guajardo Rodriguez R., Gurzo Z., Gutierrez A., Gyokeres T., Hahm K.B., Hanauer S., Hanson J., Harlan III W., Hasselblatt P., Hayee B., Hebuterne X., Hendy P., Heyman M., Higgins P., Hilal R., Hindryckx P., Hoentjen F., Hoffmann P., Holtkamp-Endemann F., Holtmann G., Horvat G., Howaldt S., Huber S., Ibegbu I., Iborra Colomino M.I., Irving P., Isaacs K., Jagarlamudi K., Jain R., Jankiel Miszputen S., Jansen J., Jones J., Karagiannis J., Karyotakis N., Kaser A., Katz L., Katz S., Kaur N., Kazenaite E., Khanna R., Khurana S., Kim J.S., Kim Y.-H., Kim S.K., Kim D., Klaus J., Kleczkowski D., Kohout P., Korczowski B., Kouklakis G., Koutroubakis I., Krause R., Kristof T., Kronborg I., Krummenerl A., Kupcinskas L., Laborda Molteni J., Laharie D., Lahat-zok A., Lee J., Lee K.-M., Leong R., Levine H., Limdi J., Lindsay J., Lodhia N., Loftus E., Longman R., Lopez Serrano P., Louis E., Louzada Pereira M.H., Lowe J., Lueth S., Lukas M., Maconi G., Macrae F., Madi-Szabo L., Mahadevan-Velayos U., Malluta E.F., Mana F., Mannon P., Mantzaris G., Marin Jimenez I., Martin Arranz M.D., Mateescu R.-B., Mazzoleni F., Meder A., Melzer E., Mertens J., Mimidis K., Mitchell B., Molnar T., Moore G., Morales Garza L.A., Mountifield R., Muls V., Murray C., Nagy B., Neurath M., Nguyen A., Panaccione R., Pandak W., Panes Diaz J., Park J., Pastorelli L., Patel B., Peck-Radosavljevic M., Pecsi G., Peerani F., Perez Gisbert J., Pesta M., Petryka R., Phillips R., Pierik M., Pratha V., Prochazka V., Racz I., Radford-Smith G., Ramos Castaneda D., Ramos Junior O., Regula J., Reimund J.-M., Robbins B., Roblin X., Rogai F., Rogler G., Rozciecha J., Rubin D., Ruiz Flores A.Y., Rupinski M., Rydzewska G., Saha S., Saibeni S., Salamon A., Sallo Z., Salzberg B., Samuel D., Samuel S., Sandborn W., Savarino E.V., Schirbel A., Schnabel R., Schreiber S., Scott J., Sedghi S., Seibold F., Seidelin J., Seidler U., Shaban A., Shafran I., Sheikh A., Sherman A., Shirin H., Smolinski P., Song G.A., Soufleris K., Speight A., Staessen D., Stallmach A., Staun M., Stein D., Steinhart H., Stifft J., Stokesberry D., Sturm A., Sultan K., Szekely G., Tagore K., Tanno H., Thin L., Thiwan S., Thomas C., Tichy M., Toth G.T., Tulassay Z., Ulbrych J., Valentine J., Varga M., Vasconcellos E., Vaughn B., Velasco B., Velazquez F., Vermeire S., Villa E., Vincze A., Vogelsang H., Volfova M., Vuitton L., Vyhnalek P., Wahab P., Walldorf J., Waterman M., Weber J., Weiss L.M., Wiechowska-Kozlowska A., Wiesner E., Witthoeft T., Wohlman R., Wozniak-Stolarska B., Yacyshyn B., Ye B.-D., Younes Z., Yukie Sassaki L., Zaltman C., and Zeuzem S.

Subjects
Adult, Male, Ulcerative Colitis Flare, medicine.medical_specialty, Asia, Adolescent, Oceania, Population, Antibodies, Monoclonal, Humanized, Injections, Subcutaneou, Placebo, Severity of Illness Index, law.invention, Middle East, Young Adult, Maintenance therapy, Randomized controlled trial, law, Internal medicine, Gastrointestinal Agent, medicine, Adverse effect, education, Aged, Aged, 80 and over, Tumor Necrosis Factor Inhibitor, education.field_of_study, Hepatology, business.industry, Remission Induction, Gastroenterology, Middle Aged, South America, medicine.disease, Ulcerative colitis, Europe, Treatment Outcome, Etrolizumab, North America, Colitis, Ulcerative, Female, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Human
Abstract

Summary Background Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission compared with placebo in patients with moderately to severely active ulcerative colitis. We aimed to evaluate the efficacy and safety of etrolizumab in patients with moderately to severely active ulcerative colitis who had been previously treated with anti-tumour necrosis factor (TNF) agents. Methods HICKORY was a multicentre, phase 3, double-blind, placebo-controlled study in adult (18–80 years) patients with moderately to severely active ulcerative colitis (Mayo Clinic total score [MCS] of 6–12 with an endoscopic subscore of ≥2, a rectal bleeding subscore of ≥1, and a stool frequency subscore of ≥1) previously treated with TNF inhibitors. Patients were recruited from 184 treatment centres across 24 countries in North America, South America, Europe, Asia, Oceania, and the Middle East. Patients needed to have an established diagnosis of ulcerative colitis for at least 3 months, corroborated by both clinical and endoscopic evidence, and evidence of disease extending at least 20 cm from the anal verge. In cohort 1, patients received open-label etrolizumab 105 mg every 4 weeks for a 14-week induction period. In cohort 2, patients were randomly assigned (4:1) to receive subcutaneous etrolizumab 105 mg or placebo every 4 weeks for the 14-week induction phase. Patients in either cohort achieving clinical response to etrolizumab induction were eligible for the maintenance phase, in which they were randomly assigned (1:1) to receive subcutaneous etrolizumab 105 mg or placebo every 4 weeks through to week 66. Randomisation was stratified by baseline concomitant treatment with corticosteroids, concomitant treatment with immunosuppressants (induction randomisation only), baseline disease activity, week 14 MCS remission status (maintenance randomisation only), and induction cohort (maintenance randomisation only). All patients and study site personnel were masked to treatment assignment. Primary endpoints were remission (Mayo Clinic total score [MCS] ≤2, with individual subscores of ≤1 and a rectal bleeding subscore of 0) at week 14, and remission at week 66 among patients with a clinical response (MCS with ≥3-point decrease and ≥30% reduction from baseline, plus ≥1 point decrease in rectal bleeding subscore or absolute rectal bleeding score of 0 or 1) at week 14. Efficacy was analysed using a modified intent-to-treat population. Safety analyses included all patients who received at least one dose of study drug during the induction phase. This study is registered at ClinicalTrials.gov , NCT02100696 . Findings HICKORY was conducted from May 21, 2014, to April 16, 2020, during which time 1081 patients were screened, and 609 deemed eligible for inclusion. 130 patients were included in cohort 1. In cohort 2,479 patients were randomly assigned to the induction phase (etrolizumab n=384, placebo n=95). 232 patients were randomly assigned to the maintenance phase (etrolizumab to etrolizumab n=117, etrolizumab to placebo n=115). At week 14, 71 (18·5%) of 384 patients in the etrolizumab group and six (6·3%) of 95 patients in the placebo group achieved the primary induction endpoint of remission (p=0·0033). No significant difference between etrolizumab and placebo was observed for the primary maintenance endpoint of remission at week 66 among patients with a clinical response at week 14 (27 [24·1%] of 112 vs 23 [20·2%] of 114; p=0·50). Four patients in the etrolizumab group reported treatment-related adverse events leading to treatment discontinuation. The proportion of patients reporting at least adverse event was similar between treatment groups for induction (etrolizumab 253 [66%] of 384; placebo 63 [66%] of 95) and maintenance (etrolizumab to etrolizumab 98 [88%] of 112; etrolizumab to placebo 97 [85%] of 114). The most common adverse event in both groups was ulcerative colitis flare. Most adverse events were mild or moderate. During induction, the most common serious adverse event was ulcerative colitis flare (etrolizumab ten [3%] of 384; placebo: two [2%] of 95). During maintenance, the most common serious adverse event in the etrolizumab to etrolizumab group was appendicitis (two [2%] of 112) and the most common serious adverse events in the etrolizumab to placebo group were ulcerative colitis flare (two [2%] of 114) and anaemia (two [2%] of 114). Interpretation HICKORY demonstrated that a significantly higher proportion of patients with moderately to severely active ulcerative colitis who had been previously treated with anti-TNF agent were able to achieve remission at week 14 when treated with etrolizumab compared with placebo; however, there was no significant difference between groups in remission at week 66 among patients with a clinical response at week 14. Funding F Hoffmann-La Roche.

Published
2022

7. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study

Author

Severine Vermeire, Peter L Lakatos, Timothy Ritter, Stephen Hanauer, Brian Bressler, Reena Khanna, Kim Isaacs, Saumin Shah, Alysha Kadva, Helen Tyrrell, Young S Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Christopher Eden, Wenhui Zhang, Brian G Feagan, Philip Abraham, Mauro Acir Crippa Júnior, Humberto Aguilar, Tasneem Ahmed, Istvan Altorjay, Vibeke Andersen, Ronen Arai, Hays Arnold, Karlee Ausk, Jeffrey Axler, Kamran Ayub, Avinash Balekuduru, Guerino Barbalaco Neto, Isaac Bassan, Brian Behm, Pradeep Bekal, Shobna Bhatia, Barnabas Bod, Carlos Eduardo Brandão Mello, Julia Brandeburova, Johannes Breedt, Ivan Chopey, Michael Connor, Richard Corlin, Carlos Alejandro Cortez Hernandez, Arijit De, Alexander de Sá Rolim, Sandra Di Felice Boratto, Tyler Dixon, Debora Dourado Poli, David Dresner, George Aaron Du Vall, Matthias Ebert, Robert Ehehalt, Atilla Ertan, Ruben Escarcega Valencia, Jason Etzel, Jan Fallingborg, Brian Feagan, Miroslav Fedurco, Enrique Fernandez Castro, Valéria Ferreira de Almeida Borges, Mark Finklestein, Andreas Fischer, Mark Fleisher, Angel Ricardo Flores Rendon, Ronald Fogel, Osvaldo Franceschi Junior, Curtis Freedland, David Gatof, Kanwar Gill, Henning Glerup, Vardaraj Gokak, Eran Goldin, Hector Alejandro Gomez Jaramillo, Nitin Gupta, Zoltan Gurzo, Olga Gyrina, Mohammed Aejaz Habeeb, Robert Hardi, William Harlan, Ammar Hemaidan, Melvin Heyman, Peter Hoffmann, William Holderman, Frank Holtkamp-Endemann, Gyula Horvat, Eran Israeli, Sender Jankiel Miszputen, Søren Jensen, Kenneth Johnson, Jennifer Jones, Osvaldo Junior, Barbora Kadleckova, Mukesh Kalla, Zsuzsanna Kallo, Nicholas Karyotakis, Lior Katz, Leo Katz, Nirmal Kaur, Pavel Kohout, Peter Lakatos, Emmanuel Larriva de los Reyes, Robert Lee, Bernard Leman, Olena Levchenko, Henry Levine, Lúcia Libanez Bessa Campelo Braga, Edward Loftus, Tetiana Lohdanidi, Randy Longman, Josefina Lozano, Christian Maaser, Laszlo Madi-Szabo, Everson Fernando Malluta, John Marshall, Francisca Martinez Silva, Kenneth Maynard, Agnieszka Meder, Chetan Mehta, Peter Minarik, Joachim Mueller, Shrikant Mukewar, Bela Nagy, Vasyl Neiko, Markus Neurath, Brian Nichol, James Novick, Nitin Pai, William Pandak, Sarat Panigrahi, Ulrich-Frank Pape, Raymundo Paraná, Nimisha Parekh, Bhaktasharan Patel, Gyula Pecsi, Sergio Peralta, Martin Pesta, Eva Peterfai, Carlo Petruzzellis, Robert Petryka, Roberta Pica, Carlos Piniella, Vijayalakshmi Pratha, Vlastimil Prochazka, Sergey Prokopchuk, Ludmyla Prystupa, Amarender Puri, Tova Rainis, Bhashyakarla Ramesh Kumar, Odery Ramos Júnior, Iaroslava Rishko, Bryan Robbins, Elizabeth Rock, Marcelo Rodrigues Borba, Miguel Rodriguez, Jerzy Rozciecha, Azalia Yuriria Ruiz Flores, Grazyna Rydzewska, Rifaat Safadi, Simone Saibeni, Anja Schirbel, Wolff Schmiegel, Róbert Schnabel, Herbert Schneider, Armando Segui, Jakob Seidelin, Ursula Seidler, Joseph Sellin, Ira Shafran, Aasim Sheikh, Alex Sherman, Haim Shirin, Akash Shukla, Firdous Siddiqui, Robert Sike, Ajit Sood, Andreas Stallmach, Mykola Stanislavchuk, Michael Staun, Daniel Stein, Alon Steinberg, Hillary Steinhart, Jonathas Stifft, Rakesh Tandon, Vishwanath Tantry, Syed Thiwan, Matthias Treiber, Jan Ulbrych, John Valentine, Rajeev Vasudeva, Byron Vaughn, Brenda Velasco, Aron Vincze, Miroslava Volfova, Mattitiahu Waterman, L. Michael Weiss, Elise Wiesner, Alonzo Williams, Thomas Witthoeft, Robert Wohlman, John Wright, Jesus Kazuo Yamamoto Furusho, Ziad Younes, Khurshid Yousuf, Yaroslav Zborivskyy, Stefan Zeuzem, and Vyacheslav Zhdan

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Population, Phases of clinical research, Placebo, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Maintenance Chemotherapy, Young Adult, Maintenance therapy, Double-Blind Method, Gastrointestinal Agents, Internal medicine, Clinical endpoint, Medicine, Humans, education, Adverse effect, Aged, education.field_of_study, Science & Technology, Hepatology, Gastroenterology & Hepatology, business.industry, Remission Induction, Gastroenterology, Colonoscopy, Middle Aged, medicine.disease, Symptom Flare Up, Ulcerative colitis, Etrolizumab, Colitis, Ulcerative, Female, business, Life Sciences & Biomedicine
Abstract

BACKGROUND: Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous phase 2 induction study, etrolizumab significantly improved clinical remission versus placebo in patients with moderately to severely active ulcerative colitis. We aimed to evaluate the efficacy and safety of etrolizumab for maintenance of remission in patients with moderately to severely active ulcerative colitis. METHODS: We conducted a randomised, placebo-controlled, double-blind, phase 3 study (LAUREL) across 111 treatment centres worldwide. We included adults (age 18-80 years) with moderately to severely active ulcerative colitis (Mayo Clinic total score [MCS] of 6-12 with an endoscopic subscore of ≥2, a rectal bleeding subscore of ≥1, and a stool frequency subscore of ≥1) who were naive to tumour necrosis factor inhibitors. Patients were required to have had an established diagnosis of ulcerative colitis for at least 3 months, corroborated by both clinical and endoscopic evidence, and evidence of disease extending at least 20 cm from the anal verge. During open-label induction, participants received subcutaneous etrolizumab 105 mg once every 4 weeks. Participants who had clinical response at week 10 (MCS with ≥3-point decrease and ≥30% reduction from baseline, plus ≥1-point decrease in rectal bleeding subscore or absolute rectal bleeding score of 0 or 1) proceeded into the double-blind maintenance phase and were randomly assigned (1:1) to receive subcutaneous etrolizumab 105 mg once every 4 weeks or matched placebo until week 62. Randomisation was stratified by baseline concomitant treatment with corticosteroids, treatment with immunosuppressants, baseline disease activity, and week 10 remission status. All participants and study site personnel were masked to treatment assignment. The primary endpoint was remission at week 62 (MCS ≤2, with individual subscores ≤1, and rectal bleeding subscore of 0) among patients with a clinical response at week 10, measured in the modified intention-to-treat population (all randomised patients who received at least one dose of study drug). This trial is registered with ClinicalTrials.gov, NCT02165215, and is now closed to recruitment. FINDINGS: Between Aug 12, 2014, and June 4, 2020, 658 patients were screened for eligibility and 359 were enrolled into the induction phase. 214 (60%) patients had a clinical response at week 10 and were randomly assigned to receive etrolizumab (n=108) or placebo (n=106) in the maintenance phase. 80 (74%) patients in the etrolizumab group and 42 (40%) in the placebo group completed the study through week 62. Four patients in the placebo group did not receive study treatment and were excluded from the analyses. At week 62, 32 (29·6%) of 108 patients in the etrolizumab group and 21 (20·6%) of 102 in the placebo group were in remission (adjusted treatment difference 7·7% [95% CI -4·2 to 19·2]; p=0·19). A greater proportion of patients reported one or more adverse events in the placebo group (82 [80%] of 102) than in the etrolizumab group (70 [65%] of 108); the most common adverse event in both groups was ulcerative colitis (16 [15%] patients in the etrolizumab group and 37 [36%] in the placebo group). Ten (9%) patients in the etrolizumab group and eight (8%) in the placebo group reported one or more serious adverse events. No deaths were reported in either treatment group. INTERPRETATION: No significant differences were observed between maintenance etrolizumab and placebo in the primary endpoint of remission at week 62 among patients who had a clinical response at week 10. Etrolizumab was well tolerated in this population and no new safety signals were identified. FUNDING: F Hoffmann-La Roche. ispartof: LANCET GASTROENTEROLOGY & HEPATOLOGY vol:7 issue:1 pages:28-37 ispartof: location:Netherlands status: published

Published
2021

8. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

Author

Rubin, David T, primary, Dotan, Iris, additional, DuVall, Aaron, additional, Bouhnik, Yoram, additional, Radford-Smith, Graham, additional, Higgins, Peter D R, additional, Mishkin, Daniel S, additional, Arrisi, Pablo, additional, Scalori, Astrid, additional, Oh, Young S, additional, Tole, Swati, additional, Chai, Akiko, additional, Chamberlain-James, Kirsten, additional, Lacey, Stuart, additional, McBride, Jacqueline, additional, Panés, Julian, additional, Rustem, Abdulkhakov, additional, Norasiah, Abu Bakar, additional, Humberto, Aguilar, additional, Diego, Aizenberg, additional, Hale, Akpinar, additional, Evangelos, Akriviadis, additional, Olga, Alexeeva, additional, Bagdadi, Alikhanov, additional, Andres, Alvarisqueta, additional, Ashwin, Ananthakrishnan, additional, Jane, Andrews, additional, Tomasz, Arlukowicz, additional, Nathan, Atkinson, additional, Ozlen, Atug, additional, Mauro, Bafutto, additional, Jozef, Balaz, additional, George, Bamias, additional, Marko, Banic, additional, Andrey, Baranovsky, additional, Guerino, Barbalaco Neto, additional, Metin, Basaranoglu, additional, Curtis, Baum, additional, Stefan, Baydanov, additional, William, Bennetts, additional, Fatih, Besisik, additional, Sudhir, Bhaskar, additional, Andrzej, Bielasik, additional, Leonid, Bilianskyi, additional, Bahri, Bilir, additional, Pavol, Blaha, additional, Verle, Bohman, additional, Julia, Borissova, additional, Vladimir, Borzan, additional, Francisco, Bosques-Padilla, additional, Yoram, Bouhnik, additional, James, Brooker, additional, Tetiana, Budko, additional, Igor, Budzak, additional, Ivan, Bunganic, additional, Jonathon, Chapman, additional, Azlida, Che' Aun, additional, Tatiana, Chernykh, additional, Michael, Chiorean, additional, Ivan, Chopey, additional, Dimitrios, Christodoulou, additional, Pui Shan, Chu, additional, Galina, Chumakova, additional, Andrew, Cummins, additional, Robert, Cunliffe, additional, Mirjana, Cvetkovic, additional, Ulku, Dagli, additional, Wit Cezary, Danilkiewicz, additional, Olena, Datsenko, additional, Carlos Fernando, de Magalhães Francesconi, additional, Henry, Debinski, additional, Elena, Deminova, additional, Jelena, Derova, additional, John Nik, Ding, additional, Julia, Dmitrieva, additional, Oleg, Dolgikh, additional, Tomas, Douda, additional, Piotr, Drobinski, additional, Gerald, Dryden, additional, Pedro, Duarte Gaburri, additional, George Aaron, DuVall, additional, Mikhail, Dvorkin, additional, Craig, Ennis, additional, Yusuf, Erzin, additional, Galyna, Fadieienko, additional, Oleksandr, Fediv, additional, Olga, Fedorishina, additional, Miroslav, Fedurco, additional, Roland, Fejes, additional, Jorge, Fernandez, additional, Monica Lorena, Fernandez, additional, Lucky, Flores, additional, Bradley, Freilich, additional, Keith, Friedenberg, additional, Sergio, Fuster, additional, Beata, Gawdis-Wojnarska, additional, Fabio Leonel, Gil Parada, additional, Edgardo Daniel, Gimenez, additional, Nataliia, Golovchenko, additional, Oleksandr, Golovchenko, additional, Maciej, Gonciarz, additional, Can, Gonen, additional, Glenn, Gordon, additional, Milos, Gregus, additional, Vladimir, Grinevich, additional, Rogelio, Guajardo Rodriguez, additional, Stephen, Hall, additional, John, Hanson, additional, Marek, Hartleb, additional, Xavier, Hebuterne, additional, Peter, Hendy, additional, Robert, Herring, additional, David, Hetzel, additional, Peter, Higgins, additional, Raouf, Hilal, additional, Ida Normiha, Hilmi, additional, Tibor, Hlavaty, additional, Richard, Holman, additional, Gerald, Holtmann, additional, John, Hong, additional, Frantisek, Horvath, additional, Ihor, Hospodarskyy, additional, Irena, Hrstic, additional, Sadettin, Hulagu, additional, Luis Alberto, Ibarra Verdugo, additional, Ikechukwu, Ibegbu, additional, Stephen, Inns, additional, Vladimir, Ivashkin, additional, James, Izanec, additional, Rajesh, Jain, additional, Zofia, Jamrozik-Kruk, additional, Victor, Kamburov, additional, John, Karagiannis, additional, Tarkan, Karakan, additional, Marek, Karczewski, additional, Irina, Kasherininova, additional, Seymour, Katz, additional, Barry, Kaufman, additional, Edita, Kazenaite, additional, Irina, Kholina, additional, Sunil, Khurana, additional, Jaroslaw, Kierkus, additional, Anzela, Kiselevska, additional, Dariusz, Kleczkowski, additional, Volodymyr, Klymenko, additional, Slavko, Knezevic, additional, Malgorzata, Kondusz-Szklarz, additional, Natalya, Korablina, additional, Bartosz, Korczowski, additional, Lyubomir, Kosturkov, additional, Iskren, Kotzev, additional, Georgios, Kouklakis, additional, Ioannis, Koutroubakis, additional, Richard, Krause, additional, Ian, Kronborg, additional, Miodrag, Krstic, additional, Zeljko, Krznaric, additional, Mikolaj, Krzyzanowski, additional, Grazyna, Kulig, additional, Karin, Kull, additional, Limas, Kupcinskas, additional, Mark, Lamet, additional, Tatjana, Latinovic Radakovic, additional, Rupert, Leong, additional, Wai Keung, Leung, additional, Henry, Levine, additional, Michael Kin Kong, Li, additional, Lúcia, Libanez Bessa Campelo Braga, additional, Maria, Livzan, additional, Tetiana, Lohdanidi, additional, Maria Helena, Louzada Pereira, additional, John, Lowe, additional, Kresimir, Luetic, additional, Milan, Lukas, additional, Yurii, Lymar, additional, Finlay, Macrae, additional, Anu, Mäelt, additional, Igor, Maev, additional, Arkadiusz, Mamos, additional, Gerasimos, Mantzaris, additional, Benno, Margus, additional, Ivanka, Marinova, additional, Inna, Markevych, additional, Mario, Markov, additional, Srdjan, Markovic, additional, Juan Ricardo, Marquez Velasquez, additional, Felipe, Mazzoleni, additional, Konstantinos, Mimidis, additional, Brent, Mitchell, additional, Gregory, Moore, additional, Luis Alonso, Morales Garza, additional, Salvatore, Moscatello, additional, Yuriy, Mostovoy, additional, Reme, Mountifield, additional, Aleksandar, Nagorni, additional, Viacheslav, Neshta, additional, Andrey, Obrezan, additional, Oleksandr, Oliinyk, additional, Genoile, Oliveira Santana Silva, additional, Maria, Orzeszko, additional, Vladimir, Pavlenko, additional, Dimitar, Pavlov, additional, Mariana, Penkova, additional, Sasa, Peric, additional, Plamen, Petkov, additional, Asen, Petrov, additional, Plamen, Petrov, additional, Michaela, Petrova, additional, Raymond, Phillips, additional, Sergio, Pintor Chacon, additional, Igor, Polianskyi, additional, Ludmyla, Prystupa, additional, Mykhailo, Pugach, additional, Ana Teresa, Pugas Carvalho, additional, Aldis, Pukitis, additional, Jiri, Pumprla, additional, Volodymyr, Pyrogovskyy, additional, Istvan, Racz, additional, Graham, Radford-Smith, additional, Raja Affendi, Raja Ali, additional, Daniel, Ramos Castañeda, additional, Odery, Ramos Júnior, additional, David, Rausher, additional, Andrey, Rebrov, additional, Jaroslaw, Regula, additional, Amir, Rezk, additional, Viktoriia, Reznikova, additional, Iaroslava, Rishko, additional, Xavier, Roblin, additional, Grigory, Rodoman, additional, Carlos Arturo, Rojas Rodriguez, additional, Jerzy, Rozciecha, additional, David, Rubin, additional, Maciej, Rupinski, additional, Jacek, Rzucidlo, additional, Oleg, Sablin, additional, Halil, Sahin, additional, Rosemi, Salleh, additional, Douglas, Samuel, additional, Antonio, Scafuto Scotton, additional, Robert, Schnabel, additional, Michael, Schulman, additional, Michael, Schultz, additional, John, Scott, additional, Shahriar, Sedghi, additional, Ahmad, Shaban, additional, Marina, Shapina, additional, Natalia, Shaposhnikova, additional, Oksana, Shchukina, additional, Alex, Sherman, additional, Irina, Shumikhina, additional, Vladimir, Simanenkov, additional, Vladislav, Simonov, additional, Giedrius, Simulionis, additional, Igor, Skrypnyk, additional, Zbigniew, Sliwowski, additional, Jan, Smid, additional, Mahmood, Solaiman, additional, Najm, Soofi, additional, Konstantinos, Soufleris, additional, Zoia, Spassova, additional, Mykola, Stanislavchuk, additional, Krystyna, Stec-Michalska, additional, Jonathas, Stifft, additional, Simeon, Stoinov, additional, Girgina, Stoyanova, additional, Keith, Sultan, additional, Lindsey, Surace, additional, Dimitar, Takov, additional, Jaak, Tälli, additional, Ludmila, Tankova, additional, Hugo, Tanno, additional, Dino, Tarabar, additional, Elias, Tarakji, additional, Konstantin, Tchernev, additional, Hoi Poh, Tee, additional, Lena, Thin, additional, Carlton, Thomas, additional, Irina, Tishaeva, additional, Tsveta, Todorova, additional, Oleksandr, Tokarenko, additional, Ivars, Tolmanis, additional, Ratko, Tomasevic, additional, Vasiliy, Trofimov, additional, Zsolt, Tulassay, additional, Belkis, Unsal, additional, Alma, Uzunova-Genova, additional, John, Valentine, additional, Ekaterina, Valuyskikh, additional, Eduardo, Vasconcellos, additional, Galina, Vasileva, additional, Sergiy, Vasylyuk, additional, Byron, Vaughn, additional, Francisco, Velazquez, additional, Vadym, Vizir, additional, Borislav, Vladimirov, additional, Miroslava, Volfova, additional, Petr, Vyhnalek, additional, Ian, Wallace, additional, Marek, Waluga, additional, William, Watkins, additional, John, Weber, additional, Anna, Wiechowska-Kozlowska, additional, Nathaniel, Winstead, additional, Pawel, Wojtkiewicz, additional, Barbara, Wozniak-Stolarska, additional, Bruce, Yacyshyn, additional, Alexey, Yakovlev, additional, Ziad, Younes, additional, Lígia, Yukie Sassaki, additional, Ilhami, Yuksel, additional, Jan, Zachar, additional, Cyrla, Zaltman, additional, Natasa, Zdravkovic Petrovic, additional, Vyacheslav, Zhdan, additional, Maryna, Zinchenko, additional, and Maciej, Zymla, additional

Published
2022
Full Text
View/download PDF

10. C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab

Author

Marie P, Boyle, Alan C, Moss, Aoibhlinn M, O'Toole, Byron, Vaughn, and Adam S, Cheifetz

Subjects
Adult, Male, C-Reactive Protein, ROC Curve, Humans, Female, Middle Aged, Inflammatory Bowel Diseases, Infliximab
Abstract

Low serum infliximab concentrations are associated with an increased risk of loss of response in inflammatory bowel disease (IBD). The objective of this study was to evaluate the test characteristics of C-reactive protein (CRP) in identifying low serum infliximab concentrations in patients with IBD.We measured serum infliximab concentrations and CRP levels in patients who experienced deteriorating symptoms while on infliximab (the reactive cohort). Receiver operating characteristic (ROC) curves were used to determine the CRP concentration threshold that identified an infliximab concentration3 μg/mL at the time of loss of response. These CRP thresholds for infliximab concentration3 μg/mL were then tested in a separate validation cohort.The reactive cohort contained 111 patients and the validation cohort contained 139 patients. In 41% of participants, serum infliximab concentration was3 μg/mL. In the reactive cohort, the area under the ROC curve for CRP to identify an infliximab concentration3 μg/mL was 0.70 (95% confidence interval [CI] 0.50-0.80, P = 0.02). A CRP level above 12 mg/L in the preceding 90 days provided a 90% specificity for the later detection of infliximab concentration3 μg/mL. These test characteristics were similar in the validation cohort.CRP levels over 12 mg/L exhibit a high specificity for identifying patients with an infliximab concentration3 μg/mL. CRP may be cost-effective for identifying patients with low concentrations of infliximab at the time of, or at risk of, loss of response.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results